Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty.

[1]  R. Califf,et al.  From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. , 1989, Journal of the American College of Cardiology.

[2]  K. Wegscheider,et al.  Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). , 1989, The American journal of cardiology.

[3]  K. Lee,et al.  Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. , 1989, Journal of the American College of Cardiology.

[4]  C. Grines,et al.  A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group. , 1989, Journal of the American College of Cardiology.

[5]  D. Allen,et al.  Pathological changes after intravenous streptokinase treatment in eight patients with acute myocardial infarction. , 1989, British heart journal.

[6]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[7]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[8]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.

[9]  E. Topol,et al.  Predictors of success for coronary angioplasty performed for acute myocardial infarction. , 1988, Journal of the American College of Cardiology.

[10]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[11]  E. B. Carlson,et al.  Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. , 1988, Journal of the American College of Cardiology.

[12]  K. Lee,et al.  Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. , 1988, Circulation.

[13]  R. Califf,et al.  Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.

[14]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[15]  Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. , 1988, JAMA.

[16]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[17]  E. Topol,et al.  Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. , 1987, Journal of the American College of Cardiology.

[18]  R. Califf,et al.  Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. , 1987, Journal of the American College of Cardiology.

[19]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[20]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[21]  D. Rothbaum,et al.  Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3 year experience. , 1987, Journal of the American College of Cardiology.

[22]  E. Topol,et al.  Value of percutaneous transluminal coronary angioplasty after unsuccessful intravenous streptokinase therapy in acute myocardial infarction. , 1986, The American journal of cardiology.

[23]  J. Ritchie,et al.  Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. , 1986, Circulation.

[24]  H W Woo,et al.  Advantages and applications of the centerline method for characterizing regional ventricular function. , 1986, Circulation.

[25]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[26]  D. Holmes,et al.  Percutaneous transluminal coronary angioplasty, alone or in combination with streptokinase therapy, during acute myocardial infarction. , 1985, Mayo Clinic proceedings.

[27]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[28]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.

[29]  R. Gabriel.  IgA DEFICIENCY, HYPERTENSION, AND MULTICYSTIC RENAL DISEASE , 1976, The Lancet.

[30]  Brain Wr,et al.  Mind and matter. , 1951 .